Integrin peptide therapy Luminate shows potential of extending DME treatment.
Anti-VEGF drugs have proven to be effective treatments for diabetic macular edema, but about half of this population does not respond to anti-VEGF therapy and monthly injections can be burdensome. A readout from the DEL MAR Phase IIB Stage 2 clinical trial of the integrin peptide agent Luminate (Allegro Ophthalmics) as sequential therapy with anti-VEGF shows the potential of extending out those injections.
To read the article, please visit Retina Specialist: “Restoring Cell Function to Block VEGF”